A5031164541- Prostate Cancer Treatment and Research
- Glioma Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
- Immune cells in cancer
- Cancer Immunotherapy and Biomarkers
- Multiple and Secondary Primary Cancers
- Chronic Lymphocytic Leukemia Research
- Cancer Research and Treatments
- Economic and Financial Impacts of Cancer
- Viral-associated cancers and disorders
- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Brain Metastases and Treatment
- Radiomics and Machine Learning in Medical Imaging
- CNS Lymphoma Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Intraperitoneal and Appendiceal Malignancies
- Urinary and Genital Oncology Studies
- Hormonal and reproductive studies
- Ferroptosis and cancer prognosis
- DNA Repair Mechanisms
Augusta University
2025
Augusta University Health
2025
United States Food and Drug Administration
2021-2024
Center for Drug Evaluation and Research
2021-2024
Food and Drug Administration
2022
Cleveland Clinic
2019-2020
Memorial Hospital of Rhode Island
2015-2019
Brown University
2015-2016
Providence College
2015-2016
John Wiley & Sons (United States)
2016
On March 23, 2022, the FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, also known as 177Lu-PSMA-617) for treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated androgen receptor pathway inhibition and taxane-based chemotherapy. The recommended 177Lu-PSMA-617 dose is 7.4 gigabecquerels (GBq; 200 mCi) intravenously every 6 weeks up to six doses, or until disease progression...
On August 13, 2021, the FDA approved belzutifan (WELIREG, Merck), a first-in-class hypoxia-inducible factor (HIF) inhibitor for adult patients with von Hippel-Lindau (VHL) disease who require therapy associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. The granted approval based on clinically meaningful effects overall response rate (ORR) observed in enrolled Study MK-6482-004. All...
We performed a pooled analysis of multiple trials poly(ADP-ribose) polymerase inhibitors (PARPi) in metastatic castration-resistant prostate cancer (mCRPC) to investigate the efficacy PARPi each individual homologous recombination repair (HRR) mutated (m) gene.
This article summarizes the US Food and Drug Administration (FDA) review of data leading to approval olaparib plus abiraterone for treatment patients with deleterious or suspected
This pooled analysis of patient-level data from trials evaluated the clinical outcomes patients with metastatic renal cell carcinoma or without cytoreductive nephrectomy before a combination immune checkpoint inhibitor and antiangiogenic therapy.
BACKGROUND Antiviral therapy has altered the prognosis of patients with human immunodeficiency virus (HIV)‐associated non‐Hodgkin lymphoma (NHL), but patterns lymphoma‐directed in community are unknown. METHODS The authors analyzed National Cancer Data Base records 10,769 who were diagnosed HIV‐associated from 2004 through 2012. Changes clinical characteristics and chemotherapy delivery over time evaluated. Factors that associated not receiving studied using multivariable logistic...
Acute liver injury can be precipitated by several factors perioperatively. One of the rare identified intraoperatively is use sevoflurane, an inhalational anesthetic agent which cause significant acute hepatotoxicity. The report presents a case followed graft loss in patient who underwent kidney transplantation. developed complications resulted loss. Close postoperative monitoring patients following transplantation crucial. supports current literature describing sevoflurane as hepatotoxic...
The treatment of advanced renal cell carcinoma (RCC) has evolved dramatically over the past 30 years, as a better understanding biology disease, knowledge multiple subtypes with distinct molecular abnormalities, and improved comprehension perturbed pathways that lead to development growth RCC. This is no longer monolithic although majority tumors are clear subtype. However, progress being made in other well, profiles understood new agents show activity. Immunotherapies remain major category...
Although the role of radiation therapy and chemotherapy in primary central nervous system lymphoma (PCNSL) has evolved considerably over past decade, application treatment modalities community not been evaluated. We analyzed use chemotherapy, therapy, associated overall survival, among 9165 HIV-negative PCSNL cases reported to US National Cancer Database 2004-2013. During this time, proportion patients receiving significantly increased from 65.6% 78.8% (P for trend <.0001), whereas decreased...
Objectives: To examine the use of splenectomy, chemotherapy, and subsequent overall survival (OS) in contemporary patients with splenic lymphomas.Methods: We analyzed records 6450 various lymphomas recorded National Cancer Data Base (2004–2013). Survival was compared using Mantel-Byer test to account for guarantee-time bias, stratified by age, sex, comorbidities, lymphoma stage.Results: Splenectomy rate 58%, varied from 49% marginal zone (SMZL) 77% follicular (FL). It significantly decreased...
On December 14, 2023, the United States Food and Drug Administration (FDA) approved belzutifan (Welireg, Merck & Co., Inc.) for patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 or death-ligand 1 (PD-1/PD-L1) inhibitor vascular endothelial growth factor tyrosine kinase (VEGF-TKI). FDA granted traditional approval based on LITESPARK-005 (NCT04195750), an open-label, randomized, head-to-head trial of 746 RCC that progressed both PD-1/PD-L1 VEGF-TKI....
Despite recent drug development for non-muscle invasive bladder cancer (NMIBC), few therapies have been approved by the US Food and Drug Administration (FDA), there remains an unmet clinical need. Bacillus Calmette-Guerin (BCG) supply issues underscore importance of developing safe effective drugs NMIBC.
FDA Oncology Center's @Falleh_Fallah and colleagues discuss loss of equipoise other trial conduct challenges in an era breakthrough therapies - via @JCO_ASCO.
2537 Background: Clinical trials of bevacizumab monotherapy and TTFields have shown activity but limited clinical benefit in patients (pts) with recurrent glioblastoma (GBM), median progression-free survival (PFS) 2-4 months overall (OS) 6-9 either treatment modality. In a single-arm phase II trial, the efficacy combination pts GBM was investigated. Methods: Pts histologically confirmed or other grade IV gliomas, who had disease progression after chemoradiation were enrolled trial TTFields....
Introduction. Celiac disease is associated with an increased risk of small bowel malignancies, particularly lymphoma. Its association carcinoma less known. Case Description. We report a case 89-year-old woman celiac who experienced recurrent episodes gastrointestinal bleeding and was ultimately found to have adenocarcinoma the intestine. Discussion Evaluation. Diagnosis often delayed because need for specialized modalities, which are deferred in inpatient setting. Although resection modality...
Abstract BACKGROUND Studies of bevacizumab monotherapy and TTFields have shown activity but limited clinical benefit in patients with recurrent GBM. In an open label, single-arm, phase 2 trial, the safety efficacy combination was studied METHOD Bevacizumab-naïve histologically confirmed GBM or other grade IV glioma, disease after radiotherapy temozolomide chemotherapy, were eligible. Bevacizumab dose 10mg/kg intravenously every weeks worn at least 18 hours daily. The primary endpoint safety,...